Marcella Baldewijns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcella Baldewijns has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Benoit Beuselinck
Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
31 shared publications - Eduard Roussel
Department of Urology, University Hospitals Leuven, Leuven, Belgium
31 shared publications - Maarten Albersen
Department of Urology, University Hospitals Leuven, Leuven, Belgium
31 shared publications - Lisa Kinget
Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium
30 shared publications - Steven Joniau
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
30 shared publications - Annelies Verbiest
Department of Medical Oncology, Multidisciplinary Oncology Center Antwerp, University Hospital Antwerp, Edegem, Belgium
29 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 2 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Pathological and molecular characteristics of Clearseq molecular subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 2 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Pathological and molecular characteristics of Clearseq molecular subtypes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 3 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Distribution of IMmotion151 signatures across Clearseq subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 3 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Distribution of IMmotion151 signatures across Clearseq subtypes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 5 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Characteristics of patients who received metastasectomy with curative intent
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 5 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Characteristics of patients who received metastasectomy with curative intent
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 4 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Characteristics of patients who received debulking
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 4 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Characteristics of patients who received debulking
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 7 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the VEGFR-TKI in first-line cohort
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 7 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the VEGFR-TKI in first-line cohort
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 6 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Multivariable models within metastasectomy with curative intent cohort
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 6 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Multivariable models within metastasectomy with curative intent cohort
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 11 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the dual ICB cohort
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 11 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the dual ICB cohort
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 12 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the cohort treated with nivolumab in later line
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 12 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Patient characteristics of the cohort treated with nivolumab in later line
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Immune tumor microenvironment of Clearseq subtype. A, Heatmap displaying the expression of immune-oncology gene signatures (selected for η2 >0.06). Columns and rows are clustered (complete method). B, Bar chart displaying enriched GSEA REACTOME pathways at FDR <0.25 (<0.42 for ccrcc1). No signatures were downregulated in ccrcc1 at FDR <0.42. C, Forest plot showing HR and 95% CI of UVA Cox proportional hazards models of the correlation of the tLHP signature with OS in the Leuven cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Immune tumor microenvironment of Clearseq subtype. A, Heatmap displaying the expression of immune-oncology gene signatures (selected for η2 >0.06). Columns and rows are clustered (complete method). B, Bar chart displaying enriched GSEA REACTOME pathways at FDR <0.25 (<0.42 for ccrcc1). No signatures were downregulated in ccrcc1 at FDR <0.42. C, Forest plot showing HR and 95% CI of UVA Cox proportional hazards models of the correlation of the tLHP signature with OS in the Leuven cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Table 1 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Clearseq signatures (A) and comparison with genes included in our previous model (B) based on fresh frozen samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Table 1 from Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma
Clearseq signatures (A) and comparison with genes included in our previous model (B) based on fresh frozen samples